Find information on thousands of medical conditions and prescription drugs.

Itraconazole


Itraconazole (marketed as Sporanox® by Janssen Pharmaceutica) is an antifungal agent that is prescribed to patients with fungal infections. The drug may be given orally or intravenously. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
Ibuprofen
Idarubicin
Idebenone
IFEX
Iloprost
Imatinib mesylate
Imdur
Imipenem
Imipramine
Imiquimod
Imitrex
Imodium
Indahexal
Indapamide
Inderal
Indocin
Indometacin
Infliximab
INH
Inosine
Intal
Interferon gamma
Intralipid
Invanz
Invirase
Iontocaine
Iotrolan
Ipratropium bromide
Iproniazid
Irbesartan
Iressa
Irinotecan
Isocarboxazid
Isoflurane
Isohexal
Isoleucine
Isomonit
Isoniazid
Isoprenaline
Isordil
Isosorbide
Isosorbide dinitrate
Isosorbide mononitrate
Isotretinoin
Itraconazole
Ivermectin
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Pharmacology

The mechanism of action of itraconazole is the same as the other azole antifungals: it inhibits cytochrome P450 oxidase mediated sysnthesis of ergosterol.

Indication

Itraconazole has a broader spectrum of activity than fluconazole (but not as broad as voriconazole or posaconazole). In particular, it is active against aspergillus, which fluconazole is not. It is also licenced for use in blastomycosis, histoplasmosis and onychomycosis.

Dosing

Itraconazole is available as capsules or as an oral solution. The dose is 200mg once a day, to 400mg in severe infection. There is an intravenous preparation available in the US, but not in the UK. In the UK, if an intravenous preparation is required, then an alternative antifungal drug should be used.

The main problem with the use of itraconazole is its poor absorption, especially when given in capsule form. The oral solution is much better absorbed and should always be used in preference to the capsule. The cyclodextrin contained in the oral solution can cause an osmotic diarrhoea, and if this is a problem, then half the dose can be given as oral solution and half as capsule in order to reduce the amount of cyclodextrin given. Itraconazole capsules should always be taken with food, as this improves absorption. Itraconazole oral solution should be taken an hour before food, or two hours after food (and likewise if a combination of capsules and oral solution are used). Itraconazole should be taken with orange juice or cola, as absorption is also improved by acid. Absorption of itraconazole is impaired when taken with an antacid, H2-blocker or proton pump inhibitor.

In life-threatening situations, some doctors give an oral loading dose of 200mg three times a day for three days, before dropping down to the usual dose. Because itraconazole absorption is unreliable, blood levels should be monitored at least once a week in those patients who are being treated for life-threatening (or potentially life-threatening) fungal infections.

In intravenous dosing, four doses of itraconazole 200mg are given 12 hours apart, before changing the dose to once daily. There is no safety data for giving the intravenous preparation for more than 14 days continuously.

Adverse effects

Itraconazole is a relatively well tolerated drug (although not as well tolerated as fluconazole or voriconazole) and the range of adverse effects it produces is similar to the other azole antifungals.

  • Elevated alanine aminotransferase levels is found in 4% of people taking itraconazole
  • Congestive Heart Failure

The cyclodextrin that is used to make the syrup preparation can cause diarrhoea.

Read more at Wikipedia.org


[List your site here Free!]


AN OPEN-LABEL COMPARISON OF ORAL VORICONAZOLE AND ITRACONAZOLE FOR LONG-TERM TREATMENT OF PARACOCCIDIOIDOMYCOSIS
From Revista do Instituto de Medicina Tropical de Sao Paulo, 10/1/05 by Queiroz-Telles, F

Queiroz-Telles, F.1; Goldani, L. Z.2; Goodrich, J. M.3; Schlamm, H. T.4; Shikanai-Yasuda, M. A.5

1 UFPR - Hospital das Clinicas; 2 UFRGS - Hospital das Clinicas; 3 University of Wyoming, Laramie, USA - Zoology and Physiology; 4 Pfizer Global Research and Development - New York, NY, USA; 5 Fundacao Pro-Sangue - Hemocentro de São Paulo

Introduction and objectives: Paracoccidioidomycosis (PCM), a subacute to chronic systemic mycosis caused by Paracoccidioides brasiliensis. The aim of this study was to investigate the efficacy, safety, and tolerability of voriconazole in the long-term treatment of acute or chronic PCM. with itraconazole as control treatment. Methods: This was a randomized, multicenter, open-label, comparative study conducted in Brazil in 2000-2002, Subjects were randomized (2:1) to receive oral therapy with voriconazole or itraconazole from 6 to 12 months. Satisfactory global response (incorporating clinical, mycologie, radiologic, and serologic assessments) at end of treatment (EOT) was compared for the 2 treatment groups. Results: Fifty-three subjects received at least 1 dose of study drug: 35 received voriconazole and 18 received itraconazole. All but 4 subjects with confirmed PCM (3 on voriconazole. 1 on itraconazole) received at least 6 months of continuous study treatment. The response rates in these treatment-evaluable patients were 100% for both treatment groups, and there were no relapses after 8 weeks of follow-up in either group. All subjects presented lung involvement at baseline: 76% mucosal lesions, 53% lymphonode enlargement. 22% laryngeal involvement and 22%, cutaneous lesions due do P. brasiliensis. One case with both lung and CNS involvement. All subjects responded well to voriconazole.The most common treatment-related events included abnormal vision, chromatopsia. rash, and headache in the voriconazole group, and bradycardia, diarrhea, and headache in the itraconazole group. Two voriconazole subjects were withdrawn prematurely, as required by the protocol, due to study drug-related elevated alk phos and hepatic enzymes (ALT, AST, and GGT). The frequency of liver function test abnormalities was slightly higher in subjects receiving voriconazole compared to itraconazole, but the median changes in these parameters from baseline values were similar between treatment groups. One voriconazole subject expired after 52 days because of a rupture of an aortic aneurysm: an autopsy was performed and was negative for PCM. Conclusions: This is the first study to demonstrate that voriconazole is well tolerated and effective for the long-term treatment of PCM. References: [1] Brummer E, et al. Clin Microbiol Rev. 1993:6:89-117. [2] Blotta MH, et al. Am J Trop Med Hyg. 1999:61:390-4. [3] Perfect JR, et al. Clin Infect Dis. 2003:36:1122-31. [4] Almeida SM, et al. ./ Infect. 2004:48:193-8.

Copyright Instituto de Medicina Tropical de Sao Paulo Oct 2005
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Itraconazole
Home Contact Resources Exchange Links ebay